Exploring Innovative Leishmaniasis Treatment: Drug Targets from Pre-Clinical to Clinical Findings

• Tipo: Outra Publicação em Revista Científica Internacional
• Data: 2021

Autores

Santana, W (Autor) Outra; de Oliveira, SSC (Autor) Outra; Ramos, MH (Autor) Outra; Santos, ALS (Autor) Outra; Dolabella, SS (Autor) Outra; Souto, EB (Autor) Outra; Severino, P (Autor) Outra; Jain, S (Autor) Outra

Revista

Título: Chemistry and Biodiversity

Vol. 18

ISSN: 1612-1872

Editora: Wiley-Blackwell

Indexação

ISI Web of Knowledge - 0 Citações

Classificação Científica

CORDIS: Ciências da Saúde

Outras Informações

ID Authenticus: P-00V-9PV

DOI: 10.1002/cbdv.202100336

Abstract (EN): Leishmaniasis is a group of tropical diseases caused by parasitic protozoa belonging to the genus Leishmania. The disease is categorized in cutaneous leishmaniasis (CL), mucocutaneous leishmaniasis (MCL), and visceral leishmaniasis (VL). The conventional treatment is complex and can present high toxicity and therapeutic failures. Thus, there is a continuing need to develop new treatments. In this review, we focus on the novel molecules described in the literature with potential leishmanicidal activity, categorizing them in pre-clinical (in vitro, in vivo), drug repurposing and clinical research.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 17